๐๐ซ๐ข๐ฆ๐š๐ซ๐ฒ ๐’๐œ๐ฅ๐ž๐ซ๐จ๐ฌ๐ข๐ง๐  ๐‚๐ก๐จ๐ฅ๐š๐ง๐ ๐ข๐ญ๐ข๐ฌ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐ˆ๐ง๐๐ฎ๐ฌ๐ญ๐ซ๐ฒ ๐€๐ง๐š๐ฅ๐ฒ๐ฌ๐ข๐ฌ ๐š๐ง๐ ๐…๐ฎ๐ญ๐ฎ๐ซ๐ž ๐›๐ฒ 2032

๐‘๐ž๐š๐ ๐ฆ๐จ๐ซ๐ž: https://www.reportsandinsights.....com/report/primary-

Business

The global primary sclerosing cholangitis market was valued at US$ 162.3 Million in 2023 and is expected to register a CAGR of 7.8% over the forecast period and reach US$ 319.1 Mn in 2032.